June 16, 2021
PAR-21-157 - The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed)
National Institute on Aging (NIA)
This notice informs potential applicants of changes to the Key Dates for Funding Opportunity Announcement (FOA) PAR-21-157 “The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed). NIA is adding a receipt date of August 16, 2021 and changing the November 18, 2021 receipt date to February 1, 2022.
The following Section of PAR-21-157 has been modified:
Part 1. Overview Information
Key Dates
Currently Reads:
Letter of Intent Due Date(s): March 26, 2021
Application Due Dates: April 26, 2021, November 18, 2021
Scientific Merit Review: July 2021, March 2022
Advisory Council Review: August 2021, May 2022
Earliest Start Date: September 2021, July 2022
Expiration Date: November 19, 2021
Modified to Read (changes shown in bold italics):
Letter of Intent Due Date(s): March 26, 2021; July 16, 2021; and January 1, 2022
Application Due Dates: April 26, 2021; August 16, 2021; and February 1, 2022
Scientific Merit Review: July 2021, October 2021; and July 2022
Advisory Council Review: August 2021, January 2022, August 2022
Earliest Start Date: September 2021, April 2022, September 2022
Expiration Date: February 2, 2022
All other aspects of this FOA remain unchanged.
Dana Jeffrey Plude, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: dana.plude@nih.gov